-
公开(公告)号：KR101490586B1
公开(公告)日：2015-02-05
申请号：KR1020130041359
申请日：2013-04-16
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61K38/17 , C12N15/63 , C12N15/12
Abstract: 본 발명은 Rcan3를 활성화시키는 항산화제의 신규 용도에 관한 것으로, 자세하게는 Rcan3 유전자 발현을 증가시키는 활성을 갖는 항산화제; 항산화제를 세포에 처리하는 단계를 포함하는 Rcan3 유전자 발현을 증가시키는 방법; 및 Rcan3 단백질을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 항산화제는 Rcan3의 유전자 발현을 효과적으로 증대시킬 수 있는 신규 용도를 가지므로, 이를 이용하여 Rcan3 단백질을 용이하게 증폭시킬 수 있고, 이렇게 증폭된 Rcan3 단백질은 칼시뉴린 경로를 억제할 수 있어 면역질환을 예방 또는 치료할 수 있는 면역 억제제로서 유용하게 사용할 수 있다. 또한, 상기 Rcan3 단백질은 천연 단백질로서 독성 및 부작용도 없어 장기간 안심하고 사용할 수 있으며, 체내에 대해 안정한 효과가 있다.
-
82.发明公开ＰＩＮＫ 1 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물 有权用于治疗或预防包含PTEN诱导的激酶1蛋白或核苷酸的自身免疫疾病的组合物
公开(公告)号：KR1020140137145A
公开(公告)日：2014-12-02
申请号：KR1020130057659
申请日：2013-05-22
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/45 , A61K48/005 , C12N9/12 , C12Y207/11001
Abstract: 본 발명은 PINK 1 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 PINK1(PTEN-induced kinase 1) 단백질은 Th17의 활성을 억제시키거나, 조절 T 세포(Regulatory T cell: Treg)의 활성을 촉진시키며, Treg세포에서 자가소화작용(autophage)를 증가시켜 과도한 면역반응을 조절하는 기작을 통해 이루어지므로 관절염 등 각종 면역반응의 조절 이상으로 유발되는 자가면역질환을 예방 또는 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용할 수 있다.
Abstract translation: 本发明涉及用于预防或治疗包括PTEN诱导的激酶1蛋白（PINK1）或用于编码PINK1作为活性成分的多核苷酸的自身免疫性疾病的组合物。 本发明的PINK1抑制Th17的活性或促进调节性T细胞（Treg）的活性，并通过增加Treg中的自噬来控制过度的免疫反应，因此PINK1可广泛用于预防或治疗自身免疫性疾病 由于不能作为药物组合物或免疫抑制剂控制免疫反应而引起的关节炎。
-
公开(公告)号：KR101436728B1
公开(公告)日：2014-09-02
申请号：KR1020130028982
申请日：2013-03-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61K35/28 , A61P37/00
Abstract: 본 발명은 골수유래억제세포(Myeloid derived suppressor cells: MDSC)와 레바미피드를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 골수유래억제세포 및 레바미피드(rebamipide)를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물, 상기 조성물을 포함하는 면역억제제 및 인간을 제외한 면역질환이 유발된 개체에 골수유래억제세포와 레바미피드를 병용 투여하는 단계를 포함하는 면역질환의 치료방법에 관한 것이다. 본 발명에 따른 골수유래억제세포(MDSC)와 레바미피드 병용투여에 의한 면역질환의 치료는 면역조절 T 세포(Treg)의 활성을 촉진시키고 자가면역항체의 수준을 감소시켜 과도한 면역반응을 조절하는 기작을 통해 이루어지므로, 염증반응 및 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 효과적으로 치료할 수 있는 효과가 있다.
-
公开(公告)号：KR1020140089315A
公开(公告)日：2014-07-14
申请号：KR1020140000937
申请日：2014-01-03
Applicant: 가톨릭대학교 산학협력단
IPC: A61K36/234 , A61P19/02 , A61P19/00
Abstract: The present invention relates to a composition for preventing or treating arthritis or osteoporosis comprising extract of glehnia littoralis as an active ingredient. According to the present invention, the extract of glehnia littoralis has excellent activity to reduce or inhibit activity of inflammatory cytokines such as IL-17, IL-6, or TNF-, and has an improved effect of reducing osteoclast differentiation, thereby being used as a composition for preventing or treating arthritis or osteoporosis. Also, the extract of glehnia littoralis does not cause cytotoxicity, has no toxicity and side effects to the drug, thereby being safely used even in long-term use, and can be stable in vivo.
Abstract translation: 本发明涉及一种用于预防或治疗关节炎或骨质疏松症的组合物，其包含小檗碱提取物作为活性成分。 根据本发明，小叶提取物具有优异的降低或抑制IL-17，IL-6或TNF-α等炎性细胞因子活性的活性，具有改善破骨细胞分化的作用，从而被用作 用于预防或治疗关节炎或骨质疏松症的组合物。 而且，小檗提取物不会引起细胞毒性，对药物无毒副作用，即使长期使用也能安全使用，可在体内稳定。
-
85.发明公开간엽줄기세포 및 면역조절 T 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 有权用于预防或治疗包含MESENCHYMAL STEM细胞和调节性T细胞的免疫疾病的细胞治疗组合物
公开(公告)号：KR1020140040696A
公开(公告)日：2014-04-03
申请号：KR1020137021403
申请日：2012-02-17
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/28 , A61K31/21 , A61K35/17 , A61K39/001 , A61K2039/5158 , C12N5/0637 , C12N5/0667 , C12N2501/15 , C12N2501/51 , C12N2501/515 , A61K2300/00
Abstract: The present invention relates to a cell therapy composition for preventing or treating immune diseases comprising mesenchymal stem cells and immunoregulatory T-cells as active ingredients. By infusing the mesenchymal stem cells and the immunoregulatory T-cells, which are cellular therapeutic agents of the present invention, into bone marrow transplanted animals, rejection to a host is suppressed after an engraftment of the transplanted bone marrow, thereby obtaining an effect of reducing immune diseases, such as graft-versus-host disease (GVHD). Moreover, the effect of such GVHD reduction is significantly greater than that of a reduction level obtained from a sole infusion of mesenchymal stem cells. Accordingly, the cell therapy composition of the present invention having such effects can be useful in the prevention or treatment of immune diseases. [Reference numerals] (AA) First experimental group; (BB) Second experimental group; (CC) Control group
Abstract translation: 本发明涉及用于预防或治疗包含间充质干细胞和免疫调节性T细胞作为活性成分的免疫疾病的细胞治疗组合物。 通过将作为本发明的细胞治疗剂的间充质干细胞和免疫调节性T细胞注入骨髓移植动物中，移植移植的骨髓被移植后抑制宿主的排斥，从而获得降低 免疫疾病，如移植物抗宿主病（GVHD）。 此外，这种GVHD降低的效果显着大于从单次输注间充质干细胞获得的还原水平的效果。 因此，具有这种效果的本发明的细胞治疗组合物可用于预防或治疗免疫疾病。 （附图标记）（AA）第一实验组; （BB）第二实验组; （CC）对照组
-
Patent Agency Ranking
公开(公告)号：KR1020130129496A
公开(公告)日：2013-11-29
申请号：KR1020120053393
申请日：2012-05-21
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K31/09 , A23L1/30
CPC classification number: A61K31/155 , A23L33/10 , A23V2002/00 , A23V2200/324 , A61K31/09 , A61K2121/00 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical use of a metformin compound used to prevent or treat immune diseases caused by abnormal immune responses, and more particularly, to a composition for preventing or treating immune diseases comprising a metformin compound as an active gradient. The metformin compound has excellent effects of inhibiting the differentiation into cytotoxic Th17 cells that generate and secrete inflammatory cytokine; enhancing activity of immunoregulatory T cells (Treg) that inhibit functions of abnormally activated immune cells and regulate inflammatory responses; and effectively maintaining and enhancing functions of the immunoregulatory T cells (Treg) through inhibition of plasticity of differentiation of the immunoregulatory T cells (Treg) into Th17 cells. Therefore, the metformin compound is useful as a pharmaceutical composition or an immune inhibitor capable of preventing or treating immune diseases caused by abnormal regulations of various immune responses, such as autoimmune diseases, inflammatory diseases, and transplant rejection disorders.
Abstract translation: 本发明涉及用于预防或治疗由免疫反应异常引起的免疫疾病的二甲双胍化合物的药物用途，更具体地涉及包含二甲双胍化合物作为活性梯度的预防或治疗免疫疾病的组合物。 二甲双胍化合物具有抑制分化为产生和分泌炎性细胞因子的细胞毒性Th17细胞的优异效果; 增强抑制异常活化免疫细胞功能和调节炎症反应的免疫调节性T细胞（Treg）的活性; 通过抑制免疫调节性T细胞（Treg）分化为Th17细胞的可塑性，有效维持和增强免疫调节性T细胞（Treg）的功能。 因此，二甲双胍化合物可用作能够预防或治疗由诸如自身免疫性疾病，炎性疾病和移植排斥障碍等各种免疫应答的异常调节引起的免疫疾病的药物组合物或免疫抑制剂。
-
公开(公告)号：KR1020130126554A
公开(公告)日：2013-11-20
申请号：KR1020130053814
申请日：2013-05-13
Applicant: 가톨릭대학교 산학협력단
IPC: G01N33/53 , G01N33/563 , C12Q1/02
CPC classification number: G01N33/5091 , G01N33/56966 , G01N33/56972 , G01N33/56977 , G01N33/6866 , G01N33/6869 , G01N2333/57 , G01N2800/245
Abstract: The present invention relates to a monitoring kit for an immune status after transplantation, and more particularly, a monitoring kit for the immune status after the transplantation, containing materials for measuring Th17 cells, Treg cells, Th1 cells, CD8EM(CD8 effect memory) IFN-γ-positive cells, and CD8CM(CD8 central memory) IFN-γ-positive cells, and a monitoring method for the immune status of the individual receiving the transplantation including a step of measuring the cell number of Th17 cells, Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the peripheral blood of an object receiving the transplantation, and a step for calculating each cell number ratio of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the number of Th17 cells by dividing the measured values of cell numbers of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells with the measured value of the cell number of Th17 cells. The monitoring method and kit for the immune status of the individual receiving the transplantation provided by the present invention are capable of determining the immune status with ease and accuracy, thereby reducing the excessive use of an immunosuppressant prescribed after transplantation and managing the immune status of each patient. [Reference numerals] (AA,EE,II,MM,QQ,UU) Normally take CNI (100% taking);(BB,DD,FF,HH,JJ,LL,NN,PP,RR,TT,VV,XX) Reduce CNI by 25% (75% taking);(CC,GG,KK,OO,SS,WW) Reduce CNI 50% (50% taking)
Abstract translation: 本发明涉及用于移植后免疫状态的监测试剂盒，更具体地，涉及用于移植后免疫状态的监测试剂盒，其包含用于测量Th17细胞，Treg细胞，Th1细胞，CD8EM（CD8效应记忆）IFN - γ阳性细胞和CD8CM（CD8中枢记忆）IFN-γ阳性细胞，以及接受移植的个体的免疫状态的监测方法，包括测量Th17细胞，Treg细胞的细胞数的步骤 ，Th1细胞，CD8EM IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞对抗接受移植的对象的外周血，以及计算Treg细胞，Th1细胞，CD8EM的每个细胞数比例的步骤 通过将Treg细胞，Th1细胞，CD8EM IFN-γ阳性细胞和CD8CM IFN的细胞数量的测量值除以相对于Th17细胞数量的IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞 - ＆伽马; -posi T细胞与Th17细胞的细胞数量的测量值。 本发明提供的接受移植的个体的免疫状态的监测方法和试剂盒能够容易且准确地测定免疫状态，从而减少移植后规定的免疫抑制剂的过度使用，并且管理每种免疫抑制剂的免疫状态 患者。 （AA，EE，II，MM，QQ，UU）通常采用CNI（100％服用）;（BB，DD，FF，HH，JJ，LL，NN，PP，RR，TT，VV，XX ）将CNI降低25％（75％服用）;（CC，GG，KK，OO，SS，WW）减少CNI 50％（50％服用）
-
公开(公告)号：KR1020130122555A
公开(公告)日：2013-11-07
申请号：KR1020130045995
申请日：2013-04-25
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/12 , C12N5/0783 , A61P37/00
Abstract: The present invention relates to novel uses of curcumin which inhibits differentiation plasticity of regulatory T cells (Treg) and, specifically, to a composition for suppressing differentiation of regulatory T cells (Treg) including curcumin as an active ingredient into etiology cells; a composition for preventing or treating autoimmune diseases including curcumin and regulatory T cells (Treg) as active ingredients; a method of manufacturing regulatory T cells (Treg) which maintains immune suppressing function using curcumin; and a method for suppressing conversion of regulatory T cells (Treg) into etiology cells by using curcumin. The curcumin according to the present invention has a novel use which effectively maintains and reinforces the functions of regulatory T cells (Treg) by suppressing differentiation plasticity of the regulatory T cells into etiology cells so that the curcumin can block differentiation of regulatory T cells (Treg) into etiology cells and maximize effects of preventing or treating autoimmune diseases when the curcumin is used in parallel with the regulatory T cells (Treg) which are cell therapy products. In addition, the curcumin is a natural substance so that the curcumin can be used for long time without toxicity and side effects and have stable effects on body.
Abstract translation: 本发明涉及抑制调节性T细胞（Treg）的分化可塑性的姜黄素的新用途，具体地，涉及抑制作为活性成分的姜黄素调节性T细胞（Treg）分化为病因细胞的组合物; 用于预防或治疗包括姜黄素和调节性T细胞（Treg）作为活性成分的自身免疫性疾病的组合物; 使用姜黄素维持免疫抑制功能的调节性T细胞（Treg）的制备方法; 以及通过使用姜黄素抑制调节性T细胞（Treg）转化为病因细胞的方法。 根据本发明的姜黄素具有通过抑制调节性T细胞向病因细胞的分化可塑性而有效维持并增强调节性T细胞（Treg）的功能的新用途，使得姜黄素可以阻断调节性T细胞（Treg）的分化 ）进入病因细胞，并且当姜黄素与作为细胞治疗产品的调节性T细胞（Treg）并行使用时，预防或治疗自身免疫性疾病的效果最大化。 此外，姜黄素是天然物质，因此姜黄素可长时间使用，无毒副作用，对身体有较好的疗效。
-
公开(公告)号：KR1020130122446A
公开(公告)日：2013-11-07
申请号：KR1020120045791
申请日：2012-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/0783 , C07D307/79 , A61K35/12
CPC classification number: C12N5/0646 , A61K35/12 , C07D307/79 , C12N2502/1114
Abstract: The present invention relates to a novel use of tanshinone IIA which suppresses differentiation plasticity of regulatory T cells (Treg) and, specifically, to a composition containing tanshinone IIA as an active ingredient for suppressing differentiation of Treg cell into Th17 cells; a composition containing tanshinone IIA and Treg cells as active ingredients for preventing or treating immune diseases; and a method for producing Treg cells using tanshinone IIA, in which immunosuppressive function is maintained. According to the present invention, tanshinone IIA effectively maintains and enhances the function of Treg cells by suppressing differentiation plasticity of Treg cells into Th17 cells, thereby blocking differentiation of Treg cells into Th17 cells under a pathological condition when being alternately used with Treg cells and providing a therapeutic agent for effectively treating immune diseases.
Abstract translation: 本发明涉及抑制调节性T细胞（Treg）的分化可塑性的新丹西酮IIA的新用途，具体地，涉及含有丹参酮IIA作为抑制Treg细胞分化为Th17细胞的活性成分的组合物的新用途。 含有丹参酮IIA和Treg细胞作为预防或治疗免疫疾病的有效成分的组合物; 以及维持免疫抑制功能的使用丹参酮IIA的Treg细胞的制造方法。 根据本发明，丹参酮IIA通过抑制Treg细胞分化为Th17细胞的可塑性，有效维持和增强Treg细胞的功能，从而在与Treg细胞交替使用时在病理条件下阻断Treg细胞分化为Th17细胞，并提供 用于有效治疗免疫疾病的治疗剂。
-
公开(公告)号：KR101301262B1
公开(公告)日：2013-08-27
申请号：KR1020090101194
申请日：2009-10-23
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/495 , A61K35/28 , A61K38/00 , C12N5/0663 , C12N2501/15 , C12N2510/00 , A61K2300/00
Abstract: 본 발명의 하나이상의 구체예는 TGFβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도를 제공한다.
간엽줄기세포, 자가면역질환, CD4+CD25+ Foxp3 조절성 T 세포, Th17
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.037 seconds)
